Allergy Learning: Early Review/Testing & Efficient Diagnosis (ALERTED)

过敏学习：早期审查/测试

• 批准号: 105074
• 金额: $ 26.97万
• 依托单位: MEDIDESIGN LIMITED
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2019
• 资助国家: 英国
• 起止时间: 2019 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=105074
• 关键词: Allergy; Learning; Early; Review; Testing

"An urgent need for radical change in allergy diagnostics is illustrated by:1. Rapid growth in number of allergy sufferers e.g. incidence of food allergy in UK children doubled in 10 years, 44% of UK adults now have an allergy (_Mintel, 2010)_2. Lengthening waiting times for allergy testing (commonly over 2 years)3. The EU's annual indirect avoidable cost of untreated allergies is estimated at between €51bn and €155bn (The European Academy of Allergy and Clinical Immunology, 2016)The ALERTED Primer study ('Allergy Learning: Early Review/Testing & Efficient Diagnosis') will develop novel integrated modular technology to address these challenges, targeting low-cost, efficient, reliable, allergy diagnostics, empowering patients and clinicians, reducing waiting times and cost per patient, while providing potentially long-term epidemiological information.The project seeks to combine new technology with a step-change in methodology and treatment. It is anticipated that early diagnosis of allergies allowing for prompt treatment will avert avoidable crises and substantially improve patient experience and outcomes."

1.过敏症患者数量的快速增长例如，英国儿童的食物过敏率在10年内翻了一番，44%的英国成年人现在有过敏症(_Mintel，2010)_2.延长过敏症检测的等待时间(通常超过2年)3.欧盟每年间接避免的未治疗过敏症成本估计在510亿欧元到1550亿欧元之间(欧洲过敏和临床免疫学学会，2016)警觉初级研究(‘过敏症学习：早期审查/检测和有效诊断’)将开发新的集成模块技术来应对这些挑战，该项目以低成本、高效、可靠的过敏诊断为目标，增强患者和临床医生的能力，减少等待时间和每位患者的成本，同时提供潜在的长期流行病学信息。该项目寻求将新技术与方法和治疗方法的阶段性变化相结合。预计，及早诊断过敏，以便及时治疗，将避免可避免的危机，并大大改善患者的体验和结果。“